Investor Relations

Orexo's share is listed on NasdaqOMX Stockholm, Sweden (ORX), and is available as American Depository Receipts on OTCQX market in the US (OXROY).

Share price

Name
0.00
0 SEK (0%)
HH:MM CET • 20YY-MM-DD

On November 2, we published the Q3 Interim Report. Below, Nikolaj Sørensen, CEO, summarizes the quarter and what he looks forward to in 2024:

Presentation of the Interim Report Q3 2023

 

Extraordinary General Meeting on October 26

Read the protocol from the EGM under Corporate Governance - EGM

Latest CEO Comments

NOVEMBER 2, 2023

"Approaching EBITDA in balance H2"

Read the latest CEO comments from Nikolaj Sørensen

Key financial figures

Group net revenue

629 MSEK
Last Twelve Months, Q422-Q323

Group EBITDA

-98 MSEK
Last Twelve Months, Q422-Q323

US Pharma segment EBIT

285 MSEK
Last Twelve Months, Q422-Q323

Cash position

184 MSEK
Q323

News flow

Regulatory Press Releases

IR-Contact